Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cultivated autologous limbal epithelial cells represent a cell therapy designed to treat limbal stem cell deficiency (LSCD), a condition that can lead to corneal blindness. This therapy involves harvesting a small biopsy of limbal stem cells from a patient's healthy eye. These cells are then expanded ex vivo in a laboratory setting and subsequently transplanted onto the damaged corneal surface. The transplanted cells engraft and regenerate the corneal epithelium, thereby restoring the integrity and transparency of the cornea. This process also provides a continuous reservoir of new cells to replenish the corneal surface, effectively addressing the underlying cause of LSCD.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cultivated autologous limbal epithelial cells.